Repurposed Drugs Trials for Ovarian Cancer

No abstract available
Source: The Cancer Journal - Category: Cancer & Oncology Tags: Review Articles Source Type: research

Related Links:

CONCLUSIONS SOX18 downregulation in HCC cells suppressed cell viability and metastasis, induced cell apoptosis and hindered the occurrence and progression of tumor cells by participating in the EMT process and regulating the autophagy signaling pathway AMPK/mTOR. PMID: 31427562 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
British Journal of Cancer, Published online: 22 August 2019; doi:10.1038/s41416-019-0553-zFXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
Skin metastases occur in 0.6-10.4% of patients with cancer, represent 2% of all skin tumors, and generally indicate a poor prognosis with an average survival time of under one year. Cutaneous metastases of ovarian cancer commonly are localized in the vicinity of the primary tumor secondary to spreading from the adjacent peritoneum or arising in abdominal incisional scars. Scalp and extremity lesions are rarely reported. Our now 33-year-old female patient was diagnosed with Stage IIIC low-grade serous papillary ovarian adenocarcinoma in 2010.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Condition:   Epithelial Ovarian Cancer Intervention:   Drug: adjuvant chemotherapy Sponsors:   Japanese Gynecologic Oncology Group;   Korean Gynecologic Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Concolino P, Capoluongo E Abstract Introduction: Currently, genetic testing of BRCA1/2 genes includes screening for single nucleotide variants, small insertions/deletions and for copy number variations (CNVs). In fact, many studies document the involvement of BRCA1/2 gene rearrangements in genetic predisposition to breast and ovarian cancer. Large genomic rearrangements (LGRs) of BRCA1 may account for up to one-third of all disease-causing alterations in various populations, while LGRs in BRCA2 are less frequently observed. Areas covered: We aimed to present an overview on current technologies employed in ...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
Ovarian cancer is one of the leading causes of cancer mortality in women. Since little clinical symptoms were shown in the early period of ovarian cancer, most patients were found in phase III-IV or with abdominal metastasis when diagnosed. The lack of effective early diagnosis biomarkers makes ovarian cancer difficult to screening. But in essence, the fundamental problem is we know very little about the regulatory mechanisms during tumorigenesis of ovarian cancer. There are emerging regulatory factors, such as long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), which have played important roles in cancers. Therefore, we...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions: As both Snail and ZEB1 are crucial inducers of epithelial-to-mesenchymal transition (EMT), our data suggested that CD44 may be crucial for the EMT process of ovarian cancer. Therefore, CD44 may be a potential prognostic marker as well as treatment target for ovarian cancer.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
T-cell engaging bispecific antibodies (biAbs) can mediate potent and specific tumor cell eradication in liquid cancers. Substantial effort has been invested in expanding this concept to solid cancers. To explore their utility in the treatment of ovarian cancer, we built a set of asymmetric biAbs in IgG1-like format that bind CD3 on T cells with a conventional scFv arm and folate receptor 1 (FOLR1) on ovarian cancer cells with a conventional or a chemically programmed Fab arm. For avidity engineering, we also built an asymmetric biAb format with a tandem Fab arm. We show that both conventional and chemically programmed CD3 ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractThe Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) calculates the probability that a woman carries a pathogenic variant inBRCA1 orBRCA2 based on her pedigree and the population frequencies of pathogenic alleles ofBRCA1 (0.0006394) andBRCA2 (0.00102) in the United Kingdom (UK). BOADICEA allows the clinician to define the population frequencies of pathogenic alleles ofBRCA1 andBRCA2 for other populations but only includes preset values for the Ashkenazy Jewish and Icelandic populations. Among 173 early-onset breast cancer pedigrees in Denmark, BOADICEA discriminated well ...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Ovarian Cancer | Ovaries